ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

NCI “Can’t Justify Size Of Intramural Program”

May 12, 1995

NCI RFAs Available

May 5, 2000

Congress Passes NIH Reauthorization.

December 15, 2006

VEGF Levels Can Predict Tumor’s Resistance to Avastin

July 29, 2011

NCI Extramural Programs: NCAB Approves Guidelines for Cancer Center Grants

March 7, 1997

SAIC-Frederick Makes Awards To Proteomics Research Teams.

January 14, 2005